Wockhardt Share Price Soars 10%; Reports Successful Use of Drug Zaynich For Cancer

Wockhardt share price soared 10% at 9:50 AM on Monday, December 16, to ₹1,536.6 on the NSE. This focus came after the company reported a significant milestone in the use of its novel drug, Zaynich (WCK 5222), in the successful treatment of a cancer patient in the US.

Zaynich was instrumental in managing the infectious process in the patient, enabling a crucial transplant after 15 days of treatment.

Zaynich Shows Promise Against Drug-Resistant Superbugs

According to Wockhardt, the pathogens involved—Pseudomonas aeruginosa and Klebsiella pneumoniae—demonstrated highly resistant mechanisms such as IMP, NDM, and OXA-48. These were effectively neutralized by Zaynich’s β-lactam enhancer mechanism, showcasing its potential against challenging superbug infections.

The company stated that Zaynich is nearing the completion of its Phase III study, a critical step toward global registration and marketing authorization.

To date, 45 patients have benefited from the compassionate use of the drug, further underscoring its promise in addressing unmet needs in antibacterial therapies targeting untreatable superbugs.

Wockhardt emphasised its focus on advancing its new drug discovery portfolio to develop innovative treatments for combating highly resistant pathogens, positioning itself as a leader in the fight against superbugs.

Stock Performance in the Last 1 Year

The stock has delivered a stellar performance in 2024, gaining 227%, marking its best calendar year since 2012 when it had surged 469%. Notably, Wockhardt shares also rose by 90% in 2023.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.